ES2509117T3 - Composición farmacéutica oral que contiene dabigatran etexilato - Google Patents
Composición farmacéutica oral que contiene dabigatran etexilato Download PDFInfo
- Publication number
- ES2509117T3 ES2509117T3 ES11704996.5T ES11704996T ES2509117T3 ES 2509117 T3 ES2509117 T3 ES 2509117T3 ES 11704996 T ES11704996 T ES 11704996T ES 2509117 T3 ES2509117 T3 ES 2509117T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- composition containing
- dabigatran etexilate
- containing dabigatran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000288 dabigatran etexilate Drugs 0.000 title abstract 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract 2
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica oral que comprende dabigatran etexilato o una sal farmacéuticamente aceptable del mismo, y un excipiente ácido inorgánico.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10155059 | 2010-03-01 | ||
EP10155059 | 2010-03-01 | ||
PCT/EP2011/052919 WO2011107427A1 (en) | 2010-03-01 | 2011-02-28 | Dabigatran etexilate-containing oral pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2509117T3 true ES2509117T3 (es) | 2014-10-17 |
Family
ID=43982233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11704996.5T Active ES2509117T3 (es) | 2010-03-01 | 2011-02-28 | Composición farmacéutica oral que contiene dabigatran etexilato |
Country Status (13)
Country | Link |
---|---|
US (1) | US20130052262A1 (es) |
EP (1) | EP2542224B1 (es) |
JP (1) | JP5801826B2 (es) |
CA (1) | CA2791561A1 (es) |
CY (1) | CY1115556T1 (es) |
DK (1) | DK2542224T3 (es) |
EA (1) | EA201201202A1 (es) |
ES (1) | ES2509117T3 (es) |
IL (1) | IL221742A (es) |
PL (1) | PL2542224T3 (es) |
PT (1) | PT2542224E (es) |
SI (1) | SI2542224T1 (es) |
WO (1) | WO2011107427A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
ITMI20110445A1 (it) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | Formulazione farmaceutica comprendente inositolo. |
CN103304539A (zh) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | 达比加群酯苹果酸盐及其制备方法和应用 |
EP2740471B1 (en) * | 2012-12-07 | 2015-05-27 | Hexal AG | Oral pharmaceutical composition comprising dabigatran etexilate |
IN2013CH05441A (es) * | 2013-11-26 | 2015-05-29 | Aurobindo Pharma Ltd | |
WO2015145462A1 (en) | 2014-03-26 | 2015-10-01 | Cadila Healthcare Limited | Pharmaceutical compositions of dabigatran |
CN105919962B (zh) * | 2015-12-18 | 2019-01-18 | 重庆两江药物研发中心有限公司 | 一种达比加群酯片剂及其制备方法 |
CN106491553A (zh) * | 2016-12-09 | 2017-03-15 | 吉林省博大伟业制药有限公司 | 一种甲磺酸达比加群酯的新合成工艺 |
JP2019014712A (ja) * | 2017-07-03 | 2019-01-31 | エルメッド エーザイ株式会社 | 安定なダビガトラン製剤 |
CN110339193B (zh) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | 含达比加群酯的药物组合物及其制备方法 |
JP2021014411A (ja) * | 2019-07-10 | 2021-02-12 | 日医工株式会社 | 安定なダビガトランエテキシラート製剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
PL210862B1 (pl) * | 2002-03-07 | 2012-03-30 | Boehringer Ingelheim Pharma | Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
GB0230034D0 (en) * | 2002-12-23 | 2003-01-29 | Biochemie Gmbh | Organic compounds |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
JP2009543843A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 直接トロンビン阻害剤に関する新規適応 |
CN101505736A (zh) * | 2006-08-25 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 控制释放系统及其制造方法 |
US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
CA2687192C (en) * | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
CN102099012A (zh) * | 2008-07-14 | 2011-06-15 | 贝林格尔.英格海姆国际有限公司 | 制备含有达比加群的药物制剂的方法 |
EP2328580A1 (en) * | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Dabigatran for percutaneous interventional cardiac catheterisation |
US9063163B2 (en) * | 2009-02-02 | 2015-06-23 | Boehringer Ingelheim International Gmbh | Lyophilised dabigatran |
-
2011
- 2011-02-28 DK DK11704996.5T patent/DK2542224T3/da active
- 2011-02-28 WO PCT/EP2011/052919 patent/WO2011107427A1/en active Application Filing
- 2011-02-28 EP EP11704996.5A patent/EP2542224B1/en active Active
- 2011-02-28 PL PL11704996T patent/PL2542224T3/pl unknown
- 2011-02-28 US US13/582,183 patent/US20130052262A1/en not_active Abandoned
- 2011-02-28 JP JP2012555381A patent/JP5801826B2/ja not_active Expired - Fee Related
- 2011-02-28 CA CA2791561A patent/CA2791561A1/en not_active Abandoned
- 2011-02-28 PT PT117049965T patent/PT2542224E/pt unknown
- 2011-02-28 ES ES11704996.5T patent/ES2509117T3/es active Active
- 2011-02-28 EA EA201201202A patent/EA201201202A1/ru unknown
- 2011-02-28 SI SI201130262T patent/SI2542224T1/sl unknown
-
2012
- 2012-09-02 IL IL221742A patent/IL221742A/en not_active IP Right Cessation
-
2014
- 2014-09-11 CY CY20141100740T patent/CY1115556T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011107427A1 (en) | 2011-09-09 |
CA2791561A1 (en) | 2011-09-09 |
EA201201202A1 (ru) | 2013-04-30 |
DK2542224T3 (da) | 2014-10-20 |
IL221742A (en) | 2015-09-24 |
PL2542224T3 (pl) | 2014-12-31 |
EP2542224B1 (en) | 2014-08-13 |
SI2542224T1 (sl) | 2014-10-30 |
JP5801826B2 (ja) | 2015-10-28 |
US20130052262A1 (en) | 2013-02-28 |
JP2013521244A (ja) | 2013-06-10 |
CY1115556T1 (el) | 2017-01-04 |
PT2542224E (pt) | 2014-10-03 |
EP2542224A1 (en) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2509117T3 (es) | Composición farmacéutica oral que contiene dabigatran etexilato | |
ES2631980T3 (es) | Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables | |
ES2634490T3 (es) | Derivados de ácido napht-2-ylacetico para tratar el sida | |
ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
ES2659758T3 (es) | Antagonistas de receptores de 5-HT3 | |
ES2515168T3 (es) | Detección y tratamiento de la esquizofrenia | |
GT201600142A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
DOP2017000306A (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
CO6290686A2 (es) | Dabigatrán para la cateterización cardiaca intervencionista percutánea | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
AR128816A2 (es) | Formas de dosificación farmacéutica de perlas de cisteamina | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2012003729A1 (es) | Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. | |
DOP2012000050A (es) | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
AR059357A1 (es) | Formulaciones farmaceuticas | |
EA201170512A1 (ru) | Композиция для перорального введения | |
CR20170314A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
CO2017005544A2 (es) | Tableta multicapa que contiene fármaco inestable a la luz | |
ES2623281T3 (es) | Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. | |
ES2660019T3 (es) | Parche que contiene diclofenaco y tiocolchicósido | |
CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. |